RU2004138588A - Соединения - Google Patents
Соединения Download PDFInfo
- Publication number
- RU2004138588A RU2004138588A RU2004138588/04A RU2004138588A RU2004138588A RU 2004138588 A RU2004138588 A RU 2004138588A RU 2004138588/04 A RU2004138588/04 A RU 2004138588/04A RU 2004138588 A RU2004138588 A RU 2004138588A RU 2004138588 A RU2004138588 A RU 2004138588A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- tetrahydro
- benzazepine
- methoxy
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- -1 (4-fluorobenzyl) - [4- (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl) phenyl] amine Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 102000015554 Dopamine receptor Human genes 0.000 claims 2
- 108050004812 Dopamine receptor Proteins 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000018526 Narcotic-Related disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000142 dyskinetic effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000003533 narcotic effect Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 201000006152 substance dependence Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- YRIMOYWLZQPOEE-UHFFFAOYSA-N 4-[(8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)sulfonyl]-n-phenylaniline Chemical compound COC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1NC1=CC=CC=C1 YRIMOYWLZQPOEE-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- TWLOBNIIGJZSCO-UHFFFAOYSA-N 5-methoxy-2-methyl-6-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC1=CC=2CN(C)CC=2C=C1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC(C(F)(F)F)=C1 TWLOBNIIGJZSCO-UHFFFAOYSA-N 0.000 claims 1
- KJDKDTRDWXCQBE-UHFFFAOYSA-N 6-ethoxy-7-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.CCOC1=CC=2CCNCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 KJDKDTRDWXCQBE-UHFFFAOYSA-N 0.000 claims 1
- GBFLXYISFPKKBT-UHFFFAOYSA-N 7-(3-phenylmethoxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2CCNCCC2=CC=1S(=O)(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 GBFLXYISFPKKBT-UHFFFAOYSA-N 0.000 claims 1
- BRSYMTIKEANUDA-UHFFFAOYSA-N 7-[4-[(3-fluorophenyl)methoxy]phenyl]sulfonyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=2CCNCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC(F)=C1 BRSYMTIKEANUDA-UHFFFAOYSA-N 0.000 claims 1
- XPPNAPKUVDAYSJ-UHFFFAOYSA-N 7-[4-[(4-chlorophenoxy)methyl]phenyl]sulfonyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=2CCNCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1COC1=CC=C(Cl)C=C1 XPPNAPKUVDAYSJ-UHFFFAOYSA-N 0.000 claims 1
- SVXRQILAKMZNDQ-UHFFFAOYSA-N 7-[4-[(4-chlorophenoxy)methyl]phenyl]sulfonyl-8-ethoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCOC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1COC1=CC=C(Cl)C=C1 SVXRQILAKMZNDQ-UHFFFAOYSA-N 0.000 claims 1
- MBEUOVDJMDXVPJ-UHFFFAOYSA-N 7-[4-[(4-chlorophenoxy)methyl]phenyl]sulfonyl-8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound COC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1COC1=CC=C(Cl)C=C1 MBEUOVDJMDXVPJ-UHFFFAOYSA-N 0.000 claims 1
- HIBWHHQXUSKNOV-UHFFFAOYSA-N 7-[4-[(4-chlorophenyl)methoxy]phenyl]sulfonyl-8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound COC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(Cl)C=C1 HIBWHHQXUSKNOV-UHFFFAOYSA-N 0.000 claims 1
- SEKXUECQSDMHON-UHFFFAOYSA-N 7-[4-[(4-fluorophenoxy)methyl]phenyl]sulfonyl-n,n,3-trimethyl-1,2,4,5-tetrahydro-3-benzazepin-8-amine Chemical compound CN(C)C1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1COC1=CC=C(F)C=C1 SEKXUECQSDMHON-UHFFFAOYSA-N 0.000 claims 1
- QXSWMHVVVHYBMA-UHFFFAOYSA-N 7-[4-[(4-fluorophenyl)methyl]phenyl]sulfonyl-8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound COC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=C1)=CC=C1CC1=CC=C(F)C=C1 QXSWMHVVVHYBMA-UHFFFAOYSA-N 0.000 claims 1
- UHUDGYGVUFKLOI-UHFFFAOYSA-N 8-[4-[(2-methoxyphenyl)methoxy]phenyl]sulfonyl-3-methyl-6-phenyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound COC1=CC=CC=C1COC1=CC=C(S(=O)(=O)C=2C=C(C=3CCN(C)CCC=3C=2)C=2C=CC=CC=2)C=C1 UHUDGYGVUFKLOI-UHFFFAOYSA-N 0.000 claims 1
- ZYFKSYKCFFNTMF-UHFFFAOYSA-N 8-methoxy-3-methyl-7-(3-phenoxyphenyl)sulfonyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound COC1=CC=2CCN(C)CCC=2C=C1S(=O)(=O)C(C=1)=CC=CC=1OC1=CC=CC=C1 ZYFKSYKCFFNTMF-UHFFFAOYSA-N 0.000 claims 1
- GJMUNWIPYJCMGG-UHFFFAOYSA-N 8-methoxy-7-(3-phenoxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound COC1=CC=2CCNCCC=2C=C1S(=O)(=O)C(C=1)=CC=CC=1OC1=CC=CC=C1 GJMUNWIPYJCMGG-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AORPHQUMVNMHPO-UHFFFAOYSA-N n-[(3-methoxyphenyl)methyl]-4-[(6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)sulfonyl]-n-methylaniline Chemical compound COC1=CC=CC(CN(C)C=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=3CCNCC=3C=2)OC)=C1 AORPHQUMVNMHPO-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (12)
1. Соединение формулы (I)
в которой А и В обозначают соответственно группы –(СН2)m- и -(СН2)n–;
R1 обозначает водород или С1-6алкил;
R2 обозначает водород, галоген, гидрокси, циано, нитро, гидроксиС1-6алкил, трифторметил, трифторметокси, С1-6алкил, С1-6алкокси, С1-6фторалкокси, -(СН2)рС3-6циклоалкил, -(СН2)рОС3-6циклоалкил, -СОС1-6алкил, -SO2C1-6алкил, -SOC1-6алкил, -S-C1-6алкил, -СО2С1-6алкил, -СО2NR5R6, -SO2NR5R6, -(CH2)pNR5R6, -(СН2)рNR5COR6, возможно замещенный арил, возможно замещенный гетероарил или возможно замещенный гетероциклил;
R3 обозначает возможно замещенный арил или возможно замещенный гетероарил;
R4 обозначает водород, гидрокси, С1-6алкил, С1-6алкокси, трифторметил, трифторметокси, галоген, -OSO2CF3, -(CH2)pC3-6циклоалкил, -(СН2)qOC1-6алкил или –(СН2)рОС3-6циклоалкил;
R5 и R6 каждый, независимо, обозначает водород, С1-6алкил или вместе с атомом азота или с другими атомами, с которыми он соединен, образует азациклоалкильное кольцо или оксозамещенное азациклоалкильное кольцо;
Z обозначает –(СН2)rХ-, в которой группа –(СН2)r- соединена с радикалом R3, или -Х(СН2)r-, в которой Х соединен с радикалом R3, и в которой любая из групп -СН2- может быть замещена одной или более группами С1-6алкил;
Х обозначает кислород, группу –NR7 или группу –CH2-, причем группа –СН2- может быть замещена одной или более группами С1-6алкил;
R7 обозначает водород или группу С1-6алкил;
m и n независимо обозначают целое число, выбранное из 1 и 2;
р независимо обозначает целое число, выбранное из 0, 1, 2 и 3;
q независимо обозначает целое число, выбранное из 1, 2 и 3;
r независимо обозначает целое число, выбранное из 0, 1 и 2;
или его фармацевтически приемлемая соль или сольват.
2. Соединение формулы (I) по п.1, в которой R1 обозначает водород или С1-4алкил.
3. Соединение формулы (I) по п.1 или 2, в которой R2 обозначает водород, галоген, С1-6алкил, С1-6алкокси, С1-6алкилтио или диС1-6алкиламино.
4. Соединение формулы (I) по п.1, в которой R3 обозначает фенил.
5. Соединение формулы (I) по п.1, в которой R4 обозначает водород, С1-4алкил или С1-4алкокси.
6. Соединение формулы (I) по п.1, которое представляет собой:
7-метокси-8-(3-феноксибензолсульфонил)-2,3,4,5-тетрагидро-1H-3-бензазепин,
7-метокси-3-метил-8-(3-феноксибензолсульфонил)-2,3,4,5-тетрагидро-1Н-3-бензазепин,
7-(3-бензилоксифенилсульфонил)-2,3,4,5-тетрагидро-3-бензазепин,
7-[4-(4-хлорбензилокси)бензолсульфонил]-8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин,
(4-фторбензил)-[4-(8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин-7-сульфонил)фенил]амин,
[4-(8-метокси-3-метил-2,3,4,5-тетрагидро-1H-3-бензазепин-7-сульфонил)фенил]фениламин,
7-[4-(4-хлорфеноксиметил)бензолсульфонил]-8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин,
(4-хлорфенил)-[4-(8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин-7-сульфонил)бензил]амин,
7-[4-(4-фторбензил)бензолсульфонил]-8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин,
7-[4-(3-фторбензилокси)бензолсульфонил]-6-метокси-1,2,3,4-тетрагидроизохинолин,
и
5-метокси-2-метил-6-[4-(3-трифторметилбензилокси)бензолсульфонил]-2,3-дигидро-1Н-изоиндол,
(2-метоксибензил)-[4-(8-метокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин-7-сульфонил)фенил]амин,
7-[4-(4-хлорфеноксиметил)бензолсульфонил]-8-этокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин,
[4-(8-этокси-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин-7-сульфонил)бензил]-(2-метоксифенил)амин,
{8-[4-(4-фторфеноксиметил)бензолсульфонил]-3-метил-2,3,4,5-тетрагидро-1Н-3-бензазепин-7-ил}диметиламин,
6-этокси-7-[4-(4-фторбензилокси)бензолсульфонил]-1,2,3,4-тетрагидроизохинолин, гидрохлорид,
(3-метоксибензил)-[4-(6-метокси-1,2,3,4-тетрагидроизохинолин-7-сульфонил)фенил]метиламин, гидрохлорид,
7-[4-(4-хлорфеноксиметил)бензолсульфонил]-6-метокси-1,2,3,4-тетрагидроизохинолин, соль гидрохлорида, и
3-метил-7-[4-(2-метоксибензилокси)фенилсульфонил]-9-фенил-1,2,4,5-тетрагидро-3-бензазепин.
7. Фармацевтическая композиция, включающая соединение формулы (I) по п.1 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
8. Соединение формулы (I) или его фармацевтически приемлемая соль или сольват по п.1 для использования в терапии.
9. Применение соединения формулы (I) или его фармацевтически приемлемой соли или сольвата по п.1 для получения лекарственного средства для лечения состояния, требующего модуляции допаминового рецептора.
10. Применение соединения формулы (I) или его фармацевтически приемлемой соли или сольвата по п.1 для приготовления лекарственного средства, предназначенного для лечения психотических состояний, шизофрении, болезни Паркинсона, зависимости от веществ (наркотическая и токсикомания), дискинетических нарушений, депрессии, биполярного расстройства, состояния тревоги, расстройства познавательной способности.
11. Способ лечения состояния, при котором требуется модуляция допаминового рецептора, который включает введение млекопитающему, нуждающемуся в этом, эффективного количества соединения формулы (I) или его фармацевтически приемлемой соли или сольвата по п.1.
12. Способ лечения психотических состояний, шизофрении, болезни Паркинсона, зависимости от веществ (наркотическая и токсикомания), дискинетических нарушений, депрессии, биполярного расстройства, состояния тревоги, расстройства познавательной способности, который заключается во введении млекопитающему, нуждающемуся в этом, эффективного количества соединения формулы (I) или его фармацевтически приемлемой соли или сольвата по п.1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0212401A GB0212401D0 (en) | 2002-05-29 | 2002-05-29 | Compounds |
| GB0212401.4 | 2002-05-29 | ||
| GB0230053.1 | 2002-12-23 | ||
| GB0230053A GB0230053D0 (en) | 2002-12-23 | 2002-12-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004138588A true RU2004138588A (ru) | 2005-06-27 |
| RU2327690C2 RU2327690C2 (ru) | 2008-06-27 |
Family
ID=29585827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004138588/04A RU2327690C2 (ru) | 2002-05-29 | 2003-05-28 | Соединения |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7504392B2 (ru) |
| EP (1) | EP1511727B1 (ru) |
| JP (1) | JP4268126B2 (ru) |
| KR (1) | KR20050013196A (ru) |
| AR (1) | AR040126A1 (ru) |
| AT (1) | ATE354566T1 (ru) |
| AU (1) | AU2003232846B9 (ru) |
| BR (1) | BR0311315A (ru) |
| CA (1) | CA2486962A1 (ru) |
| CY (1) | CY1107053T1 (ru) |
| DE (1) | DE60311986T2 (ru) |
| DK (1) | DK1511727T3 (ru) |
| ES (1) | ES2279965T3 (ru) |
| IL (1) | IL165330A0 (ru) |
| IS (1) | IS2482B (ru) |
| MX (1) | MXPA04011945A (ru) |
| MY (1) | MY133587A (ru) |
| NO (1) | NO330118B1 (ru) |
| NZ (1) | NZ536694A (ru) |
| PL (1) | PL374081A1 (ru) |
| PT (1) | PT1511727E (ru) |
| RU (1) | RU2327690C2 (ru) |
| SI (1) | SI1511727T1 (ru) |
| TW (1) | TWI281914B (ru) |
| WO (1) | WO2003099786A2 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133587A (en) | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
| US7217732B2 (en) * | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
| GB0319235D0 (en) * | 2003-08-15 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327737D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327738D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compound |
| GB0327741D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505725D0 (en) * | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
| DK1888094T3 (da) * | 2005-03-31 | 2009-11-09 | Amylin Pharmaceuticals Inc | Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser |
| GB0510599D0 (en) * | 2005-05-24 | 2005-06-29 | Glaxo Group Ltd | Novel compounds |
| GB0603087D0 (en) * | 2006-02-15 | 2006-03-29 | Glaxo Group Ltd | Novel use |
| US20070293475A1 (en) * | 2006-06-20 | 2007-12-20 | Alcon Manufacturing Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| RU2009107688A (ru) * | 2006-08-04 | 2010-09-10 | Мерц Фарма Гмбх Унд Ко. Кгаа (De) | Пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства |
| ES2545275T3 (es) * | 2008-11-06 | 2015-09-09 | Ventirx Pharmaceuticals, Inc. | Métodos de síntesis de derivados de benzazepinas |
| US20180228811A1 (en) * | 2014-12-12 | 2018-08-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0266949B1 (en) | 1986-10-28 | 1990-11-28 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists |
| EP0282287B2 (en) * | 1987-03-10 | 1996-04-24 | Lion Corporation | Deodorizer |
| EP0285287A3 (en) * | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| GB8717374D0 (en) | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
| US5032604A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
| GB9127041D0 (en) | 1991-12-20 | 1992-02-19 | Fujisawa Pharmaceutical Co | New use |
| GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
| US5707987A (en) | 1994-02-25 | 1998-01-13 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivatives |
| US5684195A (en) | 1994-07-14 | 1997-11-04 | G. D. Searle & Co. | Method of preparing sulfmonamides from sulfones |
| FI974368A7 (fi) | 1995-05-29 | 1997-11-28 | Pfizer | Kasvuhormonin vapautumista edistäviä dipeptidejä |
| DE19548785A1 (de) | 1995-12-27 | 1997-07-03 | Basf Ag | Saure Polyazofarbstoffe |
| US6046210A (en) | 1996-05-11 | 2000-04-04 | Smithkline Beecham P.L.C. | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors |
| EP0922035B1 (en) | 1996-08-14 | 2001-02-07 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
| DE19638484A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| DE69829048T2 (de) | 1997-04-22 | 2006-02-09 | Euro-Celtique S.A. | Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| EP0937723A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| US6344486B1 (en) | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| DE69914931T2 (de) | 1998-10-09 | 2004-12-16 | Janssen Pharmaceutica N.V. | 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung |
| AR022230A1 (es) | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion |
| SK12452001A3 (sk) | 1999-03-03 | 2002-04-04 | The Procter & Gamble Company | Zlúčenina vytvárajúca inhibítor metaloproteinázy, farmaceutický prostriedok, spôsob prípravy liečiva a liečivo |
| CA2374947A1 (en) | 1999-05-24 | 2000-11-30 | Robert M. Scarborough | Inhibitors of factor xa |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| WO2001085695A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| US6416458B1 (en) * | 2000-07-12 | 2002-07-09 | Therion Research Inc. | Therapeutic flexible magnetic sheet and method |
| WO2002021951A1 (en) | 2000-09-14 | 2002-03-21 | Edmund Gene Butts | Curling garment brush retainer |
| DE10053799A1 (de) | 2000-10-30 | 2002-05-08 | Bayer Ag | Verwendung von Tetrahydroisochinolinsulfonamiden |
| BR0115328A (pt) * | 2000-11-14 | 2004-04-06 | Smithkline Beecham Plc | Derivados de tetraidro benzazepina úteis como moduladores dos receptores d3 de dopamina (agentes anti-psicóticos |
| WO2002046164A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
| GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| JP2005518414A (ja) | 2001-12-21 | 2005-06-23 | スミスクライン ビーチャム パブリック リミテッド カンパニー | ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用 |
| US20050090485A1 (en) | 2002-02-13 | 2005-04-28 | Bromidge Steven M. | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| CN1630642A (zh) | 2002-02-13 | 2005-06-22 | 葛兰素集团有限公司 | 苯磺酰胺衍生物 |
| AU2003218660A1 (en) | 2002-02-13 | 2003-09-04 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
| GB0210762D0 (en) | 2002-05-10 | 2002-06-19 | Glaxo Group Ltd | Compounds |
| GB0212399D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| MY133587A (en) | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
-
2003
- 2003-05-27 MY MYPI20031957A patent/MY133587A/en unknown
- 2003-05-27 TW TW092114200A patent/TWI281914B/zh not_active IP Right Cessation
- 2003-05-27 AR ARP030101854A patent/AR040126A1/es unknown
- 2003-05-28 PL PL03374081A patent/PL374081A1/xx not_active Application Discontinuation
- 2003-05-28 PT PT03755153T patent/PT1511727E/pt unknown
- 2003-05-28 MX MXPA04011945A patent/MXPA04011945A/es active IP Right Grant
- 2003-05-28 DE DE60311986T patent/DE60311986T2/de not_active Expired - Lifetime
- 2003-05-28 CA CA002486962A patent/CA2486962A1/en not_active Abandoned
- 2003-05-28 WO PCT/EP2003/005727 patent/WO2003099786A2/en not_active Ceased
- 2003-05-28 DK DK03755153T patent/DK1511727T3/da active
- 2003-05-28 KR KR10-2004-7019172A patent/KR20050013196A/ko not_active Abandoned
- 2003-05-28 EP EP03755153A patent/EP1511727B1/en not_active Expired - Lifetime
- 2003-05-28 IL IL16533003A patent/IL165330A0/xx not_active IP Right Cessation
- 2003-05-28 ES ES03755153T patent/ES2279965T3/es not_active Expired - Lifetime
- 2003-05-28 JP JP2004507444A patent/JP4268126B2/ja not_active Expired - Fee Related
- 2003-05-28 AU AU2003232846A patent/AU2003232846B9/en not_active Ceased
- 2003-05-28 NZ NZ536694A patent/NZ536694A/en not_active IP Right Cessation
- 2003-05-28 AT AT03755153T patent/ATE354566T1/de active
- 2003-05-28 RU RU2004138588/04A patent/RU2327690C2/ru not_active IP Right Cessation
- 2003-05-28 SI SI200330757T patent/SI1511727T1/sl unknown
- 2003-05-28 US US10/515,998 patent/US7504392B2/en not_active Expired - Fee Related
- 2003-05-28 BR BR0311315-9A patent/BR0311315A/pt not_active Application Discontinuation
-
2004
- 2004-12-01 IS IS7577A patent/IS2482B/is unknown
- 2004-12-27 NO NO20045659A patent/NO330118B1/no not_active IP Right Cessation
-
2007
- 2007-04-30 CY CY20071100580T patent/CY1107053T1/el unknown
-
2008
- 2008-06-24 US US12/144,917 patent/US20080269197A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004138588A (ru) | Соединения | |
| KR101542516B1 (ko) | 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물 | |
| KR20190080897A (ko) | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 | |
| RU2000121882A (ru) | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов | |
| JP2006528685A5 (ru) | ||
| AU2004253690B2 (en) | Pyrrolodihydroisoquinolines as PDE10 inhibitors | |
| JP2013525438A5 (ru) | ||
| RU2010101279A (ru) | 1-цианоциклопропильные производные в качестве ингибиторов катепсина к | |
| RU2007147413A (ru) | Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью | |
| JP2006505623A5 (ru) | ||
| RU2005117342A (ru) | Новые аминозамещенные производные дигидропиримидо [4,5d]-пиримидинона, их получение и применение в качестве фармацевтических средств | |
| RU2007121768A (ru) | Би- и трициклически замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения болезни альцгеймера | |
| JP2008507543A5 (ru) | ||
| PE20030848A1 (es) | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 | |
| RU2002118622A (ru) | Гетероциклические дигидропиримидиновые соединения | |
| JP2002543080A (ja) | ５−ｈｔ受容体リガンドとしての四環系アゼピノインドール化合物 | |
| JP2008513413A5 (ru) | ||
| CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
| JP2009513703A5 (ru) | ||
| PE20020911A1 (es) | Derivados de indol como agonistas de 5ht2 | |
| RU2406723C2 (ru) | ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| KR20100024932A (ko) | 비사이클로아닐린 유도체 | |
| KR20020069375A (ko) | 알파-2-아드레날린성 수용체 길항제로서의 1,3-이치환된피롤리딘 | |
| JP2017535536A5 (ru) | ||
| JP2003528096A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120529 |